Intestinal obstruction (IO) in patients receiving peptide receptor radionuclide therapy (PRRT) for gastro-enteropancreatic neuroendocrine tumors (GEP-NETs): Potential predictors and association with overall survival (OS)

#3173

Introduction: There are concerns for the risk of IO in patients with GEPNETs, especially in cases with peritoneal metastases or mesenteric vascular encasement.

Aim(s): To detect the impact of a) history of IO before PRRT, b) prior surgical resection of 1ry or 2ry GEPNETs, c) peritoneal metastases, and d) nodal metastases that compromise the mesenteric vessels, on the occurrence of subsequent IO in patients received PRRT (Lu-DOTATATE). Moreover, we evaluate the association of IO -before and after PRRT- with OS.

Materials and methods: We retrospectively followed patients who had received PRRT for GEPNETs. Tumor surgical resection before PRRT and the incident of IO were reviewed. We studied patients' imaging for masses that compromised the mesenteric vessels, and for the number of peritoneal metastases. We classified peritoneal metastatic disease into mild (0-5), moderate (6-10), and extensive (>10 lesions). Cox regression and multivariate analysis were used.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Hobday T, Johnson G, Halfdanarson T, Young J,

Keywords: gastrointestinal NETs, PRRT (Lu-DOTATATE), intestinal obstruction, overall survival,